<div id="readability-page-1"><p><span>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report)</span> had its price objective decreased by stock analysts at Canaccord Genuity Group  from $54.00 to $48.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. Canaccord Genuity Group's price target indicates a potential upside of 243.59% from the company's current price.</p><div><p><span></span><span>Get <strong>Intellia Therapeutics</strong> alerts:</span></p></div><ul><li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li></ul><p>Other equities analysts also recently issued reports about the stock. Wall Street Zen cut Intellia Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Sunday, January 18th. JonesTrading cut Intellia Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Tuesday, November 11th. JPMorgan Chase &amp; Co.  restated an &#34;underweight&#34; rating and issued a $5.00 target price (down from $12.00) on shares of Intellia Therapeutics in a report on Friday, November 7th. Oppenheimer  set a $27.00 price target on shares of Intellia Therapeutics in a research note on Friday, November 7th. Finally, Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Intellia Therapeutics in a research report on Thursday, January 22nd. Ten investment analysts have rated the stock with a Buy rating, nine have issued  a Hold rating and two have assigned  a Sell rating to the company. According to MarketBeat, the company presently has an average rating of &#34;Hold&#34; and an average price target of $19.14.</p><p><b>Read Our Latest Stock Analysis on NTLA</b></p><h2>Intellia Therapeutics Price Performance</h2><ul><li>Analysts Think These Stocks Could More Than Double in Value</li></ul><p>Shares of NTLA traded down $1.47 during midday trading on Tuesday, reaching $13.97. The stock had a trading volume of 7,328,557 shares, compared to its average volume of 5,436,175. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -3.65 and a beta of 2.09. The company's fifty day simple moving average is $12.01 and its two-hundred day simple moving average is $13.08. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $28.25. </p><p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.99) by $0.16. The company had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The business's quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter last year, the company posted ($1.27) earnings per share.  On average, sell-side analysts forecast that  Intellia Therapeutics will post -5.07 earnings per share for the current year. </p><h2>Insider Activity</h2><ul><li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li></ul><p>In other Intellia Therapeutics news, EVP James Basta sold 10,397 shares of the company's stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $95,756.37. Following the transaction, the executive vice president directly owned 101,528 shares of the company's stock, valued at $935,072.88. This represents a 9.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Birgit C. Schultes sold 8,508 shares of Intellia Therapeutics stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $9.21, for a total value of $78,358.68. Following the sale, the executive vice president owned 98,533 shares of the company's stock, valued at approximately $907,488.93. This represents a 7.95% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 53,051 shares of company stock worth $488,600 in the last ninety days. Corporate insiders own  3.10% of the company's stock. </p><h2>Hedge Funds Weigh In On Intellia Therapeutics</h2><p>Several hedge funds and other institutional investors have recently added to or reduced their stakes in NTLA. Oppenheimer &amp; Co. Inc. grew its stake in shares of  Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer &amp; Co. Inc. now owns 105,165 shares of the company's stock worth $945,000 after acquiring an additional 808 shares during the last quarter.  CWM LLC grew its position in  Intellia Therapeutics by 4.7% in the 3rd quarter. CWM LLC now owns 19,187 shares of the company's stock worth $331,000 after purchasing an additional 856 shares during the last quarter.  Comerica Bank increased its holdings in shares of  Intellia Therapeutics by 45.8% during the 4th quarter. Comerica Bank now owns 2,869 shares of the company's stock worth $26,000 after purchasing an additional 901 shares during the period.  Federated Hermes Inc. increased its holdings in shares of  Intellia Therapeutics by 39.7% during the 3rd quarter. Federated Hermes Inc. now owns 3,263 shares of the company's stock worth $56,000 after purchasing an additional 927 shares during the period.  Finally, Cyndeo Wealth Partners LLC raised its position in shares of  Intellia Therapeutics by 9.3% during the third quarter. Cyndeo Wealth Partners LLC now owns 11,710 shares of the company's stock valued at $202,000 after buying an additional 995 shares during the last quarter. Institutional investors own  88.77% of the company's stock. </p><h2>Key Intellia Therapeutics News</h2><p>Here are the key news stories impacting Intellia Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>FDA lifts clinical hold on MAGNITUDE Phase 3 for nex‑z, clearing the way to resume a late‑stage heart disease gene therapy trial — a major regulatory milestone that reduces near‑term program risk and supports timelines for a key asset. Read More.</li>    <li><span>Positive Sentiment: </span>Company announced presentations of three‑year follow‑up data and patient‑focused research for lonvoguran (lonvo‑z) at AAAAI; longer‑term efficacy/safety signals from a one‑time 50 mg dose could materially de‑risk that HAE program if data are favorable. Read More.</li>    <li><span>Positive Sentiment: </span>Multiple brokerages raised ratings and price targets (examples: HC Wainwright to $30, Leerink to $29, Citizens Jmp to $28; William Blair upgraded to Outperform), which can attract buy interest and provide cover for investors to re‑enter the shares. Read More. — and see William Blair upgrade coverage Read More..</li>    <li><span>Neutral Sentiment: </span>Market attention from high‑profile investors: media reported Cathie Wood (ARK) made bargain purchases this week; inclusion of NTLA in such trades can boost liquidity and short‑term interest but is not a fundamental change. Read More.</li>    <li><span>Neutral Sentiment: </span>Additional analyst activity includes RBC, Wells Fargo and others adjusting ratings/targets (some modest), reflecting mixed views on near‑term upside vs. clinical execution risk. Read More.</li>    <li><span>Negative Sentiment: </span>Underlying financials remain loss‑making: recent quarters show negative EPS, large net‑loss margins and analyst forecasts of continued negative FY2026 EPS, which keeps NTLA a high‑beta, binary biotech play dependent on clinical/regulatory outcomes.</li> </ul><h2>Intellia Therapeutics Company Profile</h2> (Get Free Report)<p>Intellia Therapeutics, Inc <span>NASDAQ: NTLA<span></span></span> is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company's research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia's lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.  </p><p>Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.</p><h2>Read More</h2><ul><li>Five stocks we like better than Intellia Therapeutics</li><li>The gold chart Wall Street is terrified of…</li><li>America’s 1776 happening again</li><li>Buy this Gold Stock Before May 2026</li><li>I'm 70 With $1.5M: Would Converting $120K a Year to a Roth Be Smart or a Costly Mistake? (Ask An Advisor)</li><li>What a Former CIA Agent Knows About the Coming Collapse</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p><p>While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

CRSP

<p>Canaccord Genuity Group has lowered its price target for Intellia Therapeutics (NASDAQ:NTLA) from $54.00 to $48.00 while maintaining a "buy" rating. This new target suggests a potential upside of 243.59% from the current price. Other analysts have varied opinions, with some downgrading their ratings. Currently, NTLA's stock is trading at $13.97, with a market cap of $1.65 billion and a negative earnings per share of -$0.83 for the last quarter. Insiders have recently sold shares, and hedge funds are adjusting their stakes in the company.</p>

Market Beat

First Trust NYSE Arca Biotech Index Fd

CRISPR Therap

VanEck Biotech ETF

Intellia Therap

iShares Genomics Immunology and Healthcare ETF

Franklin Genomic Adv ETF

Invesco Nasdaq Biotechnology ETF

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

SPDR S&P Biotech

iShares Biotechnology ETF

Wisdomtree BioRevolution Fund ETF

Proshares Ultra Nasdaq Biotech

Intellia Therapeutics (NASDAQ:NTLA) Given New $48.00 Price Target at Canaccord Genuity Group